Week in Review: BeiGene Co.,Ltd Out-Licenses Novel Cancer Drug to Merck Serono

Published: Nov 18, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

November 16, 2013 -- BeiGene of Beijing out-licensed the ex-China rights for a novel cancer treatment, a PARP inhibitor, to Merck Serono for up to $232 million in milestones; PW Medtech Group, a Beijing medical device company, completed a $180 million IPO in Hong Kong; Shanghai Kinetic Medical acquired an 80% stake in Jiangsu Ideal Medical, a fellow orthopedic implant company, for $86.7 million; Medifocus, a US medical device company, will form a JV with Ideal Concept Group of Hong Kong to develop microwave-based medical devices in China; BGI Health of Shenzhen will form a genomics partnership with Sidra Medical of Qatar; China’s pharma output will grow 20.5% in 2013, reaching $372.6 billion, though profits are not keeping pace with revenues; Merck KGaA and Johnson & Johnson each announced they will build new manufacturing facilities in China; Lilly will spend $350 million in China to increase its production of insulin cartridges; and WuXi PharmaTech said its CMO subsidiary will produce commercial supplies of Imbruvica, a newly approved lymphoma treatment developed by Pharmacyclics. More details…..

Stock Symbols: (Xetra: MRK) (HK: 1358) (SHE: 300326) (OTCQX: MDFZF; TSX: MFS) (NYSE: JNJ) (NYSE: LLY) (NYSE: WX) (NSDQ: PCYC)

Help employers find you! Check out all the jobs and post your resume.

Back to news